Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 35, 2005 - Issue 1
54
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats

, , , , , , , & show all
Pages 107-116 | Received 21 Jul 2004, Published online: 22 Sep 2008

Reference

  • Cunningham KA, Appel JB. 1986. Possible 5-hydroxytryptamine 1 (5HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP). Journal of Pharmacology and Experimental Therapeutics 237:369–377.
  • Drug Enforcement Administration (DEA), Department of Justice. 2002. Schedules of controlled substances; temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into Schedule I. Federal Register 67:59161–59162.
  • Drug Enforcement Administration (DEA), Office of Domestic Intelligence. 2002. BZP and TFMPP: chemicals used to mimic MDMA's effects. Microgram Bulletin 35:123–126.
  • Gibson GG, Skett P. 2001. Factors affecting drug metabolism: internal factors. In: Introduction to Drug Metabolism, 3rd ed. London: Taylor & Francis. p. 119–145.
  • Hernandez EJ, Williams PA, Dudek FE. 2002. Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia 43:1337–1345.
  • Herndon JL, Pierson ME, Glennon RA. 1992, Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacology Biochemistry and Behavior 43:739–748.
  • Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. 1994. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacological Reviews 46:157–203.
  • Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. 2003. Optimized glucuronide hydrolysis for the detection of psilocin I human urine samples. Journal of Chromatography B 796:421–427.
  • Karnata T, Shima N, Tsutsumi H, Nishikawa M, Katagi M, Tatsuno M, Tsuchihashi H. 2004. Analysis of the sulfate and glucuronide conjugates of p-hydroxymethamphetamine in methamphetamine users' urine by LC-ESI-MS-MS and the optomization of their hydrolysis. Paper presented at the 23rd Annual Meeting of Japanese Association of Forensic Toxicology, 22-23 April, Akita, Japan.
  • Katagi M, Tsutsumi H, Miki A, Nakajima K, Tsuchihashi H. 2003. Analyses of clandestine tablets of amphetamines and their related designer drugs encountered in recent Japan. Japanese Journal of Forensic Toxicology 20:303–319.
  • Mayo RF, Cole CA, Colson KE, Kerns EH. 1994. Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat. Drug Metabolism and Disposition 22:171–174.
  • Middlemiss DN, Tricklebank MD. 1992. Central active 5-FIT receptor agonists. Neuroscience and Biobehavioral Reviews 16:75–82.
  • Pettibone DJ, Williams M. 1984. Serotonin-releasing effects of substituted piperazines in vitro. Biochemistry and Pharmacology 33:1531–1535.
  • Schechter MD. 1988. Serotonergic-dopaminergic mediation of 3,4-methylanedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacology Biochemistry and Behavior 31:817–824.
  • Schechter MD. 1988. Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation. Pharmacology Biochemistry and Behavior 31:53–57.
  • Shima N, Karnata T, Nishikawa M, Tsuchihashi H. 2003. Examination of the hydrolysis conditions of glucuronide conjugated drug in urine. Japanese Journal of Science and Technology for identification 8(Suppl.): 79.
  • Staack RF, Fritschi G, Maurer HH. 2003. New designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. Journal of Mass Spectrometry 38:971–981.
  • Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. 2004. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochemistry and Pharmacology 67:235–244.
  • Tsutsumi H, Katagi M, Tsuchihashi H, Inoue H, Kishi T, Tsunoda N. 2004. Determination of newly controlled narcotics, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), and their related compounds. Paper presented at the 124th Annual Meeting of the Pharmaceutical Society of Japan, 29–31 March, Osaka, Japan.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.